25 results on '"Gray, Nathanael S."'
Search Results
2. SnapShot: Kinase Inhibitors II.
- Author
-
Wang, Jinhua and Gray, Nathanael S.
- Subjects
- *
KINASE inhibitors , *SMALL molecules , *PROTEIN kinases , *FUNCTION (Biology) , *DRUG development - Abstract
Selective small-molecule inhibitors of protein kinases can serve as powerful tools to elucidate biological function. Efforts to develop potential drug candidates have yielded a wealth of kinase inhibitors. However, selecting the optimal kinase inhibitor for a particular application can be challenging. While the optimal inhibitor will be application specific, we have attempted to summarize some of the best reported inhibitors for various kinases. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. SnapShot: Kinase Inhibitors I.
- Author
-
Wang, Jinhua and Gray, Nathanael S.
- Subjects
- *
KINASE inhibitors , *PROTEIN kinases , *DRUG development , *FUNCTION (Biology) , *MOLECULAR biology - Abstract
Selective small-molecule inhibitors of protein kinases can serve as powerful tools to elucidate biological function. Efforts to develop potential drug candidates have yielded a wealth of kinase inhibitors. However, selecting the optimal kinase inhibitor for a particular application can be challenging. While the optimal inhibitor will be application specific, we have attempted to summarize some of the best reported inhibitors for various kinases. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. The ins and outs of selective kinase inhibitor development.
- Author
-
Müller, Susanne, Chaikuad, Apirat, Gray, Nathanael S, and Knapp, Stefan
- Subjects
- *
KINASE inhibitors , *CRYSTAL structure , *PROTEIN kinases , *SELECTIVE inhibition (Chemistry) , *BINDING sites - Abstract
The author discusses the design strategies to improve the coverage of kinome and development of its selective inhibitors. The author investigated the crystal structure of the protein kinase domain (PKA), the location of ATP-binding site on protein kinases, and the selectivity of type III inhibitors.
- Published
- 2015
- Full Text
- View/download PDF
5. Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.
- Author
-
Giurisato, Emanuele, Qiuping Xu, Lonardi, Silvia, Telfer, Brian, Russo, Ilaria, Pearson, Adam, Finegan, Katherine G., Wenbin Wang, Jinhua Wang, Gray, Nathanael S., Vermi, William, Zhengui Xia, and Tournier, Cathy
- Subjects
- *
PROTEIN kinases , *STAT proteins , *MACROPHAGES , *TUMOR growth , *DISEASE progression , *CANCER immunotherapy - Abstract
Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few and far between because the signaling mechanisms underpinning protumor macrophage phenotypes are largely unknown. Here, we have investigated the role of the extracellular-regulated protein kinase 5 (ERK5) as a determinant of macrophage polarity. We report that the growth of carcinoma grafts was halted in myeloid ERK5-deficient mice. Coincidentally, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. Further molecular analyses demonstrated that activation of the signal transducer and activator of transcription 3 (STAT3) via Tyr705 phosphorylation was impaired in erk5-deleted TAMs. Our study thus suggests that blocking ERK5 constitutes a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
- Author
-
Weir, Mark C., Hellwig, Sabine, Tan, Li, Liu, Yao, Gray, Nathanael S., and Smithgall, Thomas E.
- Subjects
- *
ACUTE myeloid leukemia treatment , *PROTEIN-tyrosine kinases , *CELL lines , *GENETIC mutation , *APOPTOSIS - Abstract
Acute myelogenous leukemia (AML) is often associated with activating mutations in the receptor tyrosine kinase, Flt3, including internal tandem duplications (ITDs) within the regulatory juxtamembrane region. Previous studies have linked Flt3-ITD to the activation of the Fes protein tyrosine kinase in AML, and RNAi-knockdown studies suggest that Fes may be required for Flt3 function. In this study, we tested Fes inhibitors from three different chemical classes for their growth-suppressive activity against Flt3-ITD+ myeloid leukemia cell lines (MV4-11, MOLM-13 and MOLM-14) vs. myeloid cells with wild-type Flt3 (THP-1). All Fes inhibitors selectively inhibited the growth of Flt3-ITD+ AML cells, with IC50 values for diaminopyrimidine and pyrrolopyridine inhibitors ranging from 19 to 166 nM. In contrast, a pyrazolopyrimidine inhibitor was less potent in Flt3-ITD+ AML cells, with IC50 values in the 1.0 μM range. In vitro kinase assays showed that the most potent inhibitors of Flt3-ITD+ AML cell proliferation blocked both Fes and Flt3-ITD kinase activity, while the pyrazolopyrimidine was more selective for Fes vs. Flt3-ITD. All three inhibitors induced significant apoptosis in Flt3-ITD+ AML cells, with potency equivalent to or greater than the established Flt3-ITD inhibitor, tandutinib. Transformation of TF-1 cells with Flt3-ITD resulted in constitutive activation of endogenous Fes, and rendered the cells highly sensitive to all three Fes inhibitors with IC50 values in the 30–500 nM range. The pyrrolopyridine compound also induced apoptotic responses in patient-derived Flt3-ITD+ AML bone marrow cells but not in normal bone marrow mononuclear cells. These results demonstrate that Fes kinase activity contributes to Flt3-ITD signaling in AML, and suggests that dual inhibition of both Flt3 and Fes may provide a therapeutic advantage for the treatment of Flt3-ITD+ AML. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.
- Author
-
Yubao Wang, Begley, Michael, Qing Li, Hai-Tsang Huang, Lako, Ana, Eck, Michael J., Gray, Nathanael S., Mitchison, Timothy J., Cantley, Lewis C., and Zhao, Jean J.
- Subjects
- *
PROTEIN kinases , *LEUCINE zippers , *CANCER invasiveness , *CANCER cells , *MITOSIS , *CELL cycle - Abstract
The protein kinase maternal and embryonic leucine zipper kinase (MELK) is critical for mitotic progression of cancer cells; however, its mechanisms of action remain largely unknown. By combined approaches of immunoprecipitation/mass spectrometry and peptide library profiling, we identified the eukaryotic translation initiation factor 4B (eIF4B) as a MELK-interacting protein during mitosis and a bona fide substrate of MELK. MELK phosphorylates eIF4B at Ser406, a modification found to be most robust in the mitotic phase of the cell cycle. We further show that the MELK-eIF4B signaling axis regulates protein synthesis during mitosis. Specifically, synthesis of myeloid cell leukemia 1 (MCL1), an antiapoptotic protein known to play a role in cancer cell survival during cell division, depends on the function of MELK-elF4B. Inactivation of MELK or eIF4B results in reduced protein synthesis of MCL1, which, in turn, induces apoptotic cell death of cancer cells. Our study thus defines a MELK-eIF4B signaling axis that regulates protein synthesis during mitosis, and consequently influences cancer cell survival. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis.
- Author
-
Lee, Sebum, Shang, Yulei, Redmond, Stephanie A., Urisman, Anatoly, Tang, Amy A., Li, Kathy H., Burlingame, Alma L., Pak, Ryan A., Jovičić, Ana, Gitler, Aaron D., Wang, Jinhua, Gray, Nathanael S., Seeley, William W., Siddique, Teepu, Bigio, Eileen H., Lee, Virginia M.-Y., Trojanowski, John Q., Chan, Jonah R., and Huang, Eric J.
- Subjects
- *
NEURODEGENERATION , *AMYOTROPHIC lateral sclerosis , *HOMEOBOX proteins , *PROTEIN kinases , *ENDOPLASMIC reticulum - Abstract
Summary Persistent accumulation of misfolded proteins causes endoplasmic reticulum (ER) stress, a prominent feature in many neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Here we report the identification of homeodomain interacting protein kinase 2 (HIPK2) as the essential link that promotes ER-stress-induced cell death via the IRE1α-ASK1-JNK pathway. ER stress, induced by tunicamycin or SOD1 G93A , activates HIPK2 by phosphorylating highly conserved serine and threonine residues (S359/T360) within the activation loop of the HIPK2 kinase domain. In SOD1 G93A mice, loss of HIPK2 delays disease onset, reduces cell death in spinal motor neurons, mitigates glial pathology, and improves survival. Remarkably, HIPK2 activation positively correlates with TDP-43 proteinopathy in NEFH -tTA/ tetO -hTDP-43ΔNLS mice, sporadic ALS and C9ORF72 ALS, and blocking HIPK2 kinase activity protects motor neurons from TDP-43 cytotoxicity. These results reveal a previously unrecognized role of HIPK2 activation in ER-stress-mediated neurodegeneration and its potential role as a biomarker and therapeutic target for ALS. Video Abstract [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Inhibition of IKKα by BAY61-3606 Reveals IKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells.
- Author
-
Ho, Catherine M. K., Donovan-Banfield, I’ah Z., Tan, Li, Zhang, Tinghu, Gray, Nathanael S., and Strang, Blair L.
- Subjects
- *
HISTONES , *PHOSPHORYLATION , *HUMAN cytomegalovirus diseases , *PROTEIN kinase inhibitors , *VIRAL replication - Abstract
Protein kinase inhibitors can be used as tools to identify proteins and pathways required for virus replication. Using virus replication assays and western blotting we found that the widely used protein kinase inhibitor BAY61-3606 inhibits replication of human cytomegalovirus (HCMV) strain AD169 and the accumulation of HCMV immediate-early proteins in AD169 infected cells, but has no effect on replication of HCMV strain Merlin. Using in vitro kinase assays we found that BAY61-3606 is a potent inhibitor of the cellular kinase IKKα. Infection of cells treated with siRNA targeting IKKα indicated IKKα was required for efficient AD169 replication and immediate-early protein production. We hypothesized that IKKα was required for AD169 immediate-early protein production as part of the canonical NF-κB signaling pathway. However, although BAY61-3606 inhibited phosphorylation of the IKKα substrate IκBα, we found no canonical or non-canonical NF-κB signaling in AD169 infected cells. Rather, we observed that treatment of cells with BAY61-3606 or siRNA targeting IKKα decreased phosphorylation of histone H3 at serine 10 (H3S10p) in western blotting assays. Furthermore, we found treatment of cells with BAY61-3606, but not siRNA targeting IKKα, inhibited the accumulation of histone H3 acetylation (H3K9ac, H3K18ac and H3K27ac) and tri-methylation (H3K27me3 and H3K36me3) modifications. Therefore, the requirement for IKKα in HCMV replication was strain-dependent and during replication of an HCMV strain requiring IKKα, IKKα-dependent H3S10 phosphorylation was associated with efficient HCMV replication and immediate-early protein production. Plus, inhibition of HCMV replication by BAY61-3606 is associated with acetylation and tri-methylation modifications of histone H3 that do not involve IKKα. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. X-rayCrystal Structure of ERK5 (MAPK7) inComplex with a Specific Inhibitor.
- Author
-
Elkins, Jonathan M., Wang, Jing, Deng, Xianming, Pattison, Michael J., Arthur, J. Simon C., Erazo, Tatiana, Gomez, Nestor, Lizcano, Jose M., Gray, Nathanael S., and Knapp, Stefan
- Subjects
- *
CRYSTAL structure , *PROTEIN kinases , *CHEMICAL inhibitors , *TARGETED drug delivery , *CANCER cell proliferation , *EPITHELIAL cells , *MESENCHYMAL stem cells - Abstract
Theprotein kinase ERK5 (MAPK7) is an emerging drug target fora variety of indications, in particular for cancer where it playsa key role mediating cell proliferation, survival, epithelial–mesenchymaltransition, and angiogenesis. To date, no three-dimensional structurehas been published that would allow rational design of inhibitors.To address this, we determined the X-ray crystal structure of thehuman ERK5 kinase domain in complex with a highly specific benzo[e]pyrimido[5,4-b]diazepine-6(11H)-one inhibitor. The structure reveals that specific residuedifferences in the ATP-binding site, compared to the related ERKsp38s and JNKs, allow for the development of ERK5-specific inhibitors.The selectivity of previously observed ERK5 inhibitors can also berationalized using this structure, which provides a template for futuredevelopment of inhibitors with potential for treatment of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- Author
-
Liu, Qingsong, Sabnis, Yogesh, Zhao, Zheng, Zhang, Tinghu, Buhrlage, Sara J., Jones, Lyn H., and Gray, Nathanael S.
- Subjects
- *
PROTEIN kinases , *CELLULAR signal transduction , *GENETIC mutation , *PHARMACODYNAMICS , *KINASE inhibitors , *TARGETED drug delivery , *CYSTEINE - Abstract
Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To date, the majority of clinical and preclinical kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential “kinase cysteinome” and discuss strategies for the efficient development of new covalent inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. A public-private partnership to unlock the untargeted kinome.
- Author
-
Knapp, Stefan, Arruda, Paulo, Blagg, Julian, Burley, Stephen, Drewry, David H, Edwards, Aled, Fabbro, Doriano, Gillespie, Paul, Gray, Nathanael S, Kuster, Bernhard, Lackey, Karen E, Mazzafera, Paulo, Tomkinson, Nicholas C O, Willson, Timothy M, Workman, Paul, and Zuercher, William J
- Subjects
- *
PUBLIC-private sector cooperation , *LIGANDS (Biochemistry) , *PROTEIN kinases , *ENZYME inhibitors , *CYTOLOGY - Abstract
The author discusses the methods to unlock untargeted kinase in partnering with public and private sector. He mentions that only 518 human protein kinases have been annotated with small molecule inhibitors despite their prime role in cellular function of body. Also investigated is the possible effort that is made to optimize kinase ligands with defined methods for the execution of highly selective inhibitors.
- Published
- 2012
- Full Text
- View/download PDF
13. High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors
- Author
-
Miduturu, Chandrasekhar V., Deng, Xianming, Kwiatkowski, Nicholas, Yang, Wannian, Brault, Laurent, Filippakopoulos, Panagis, Chung, Eunah, Yang, Qingkai, Schwaller, Juerg, Knapp, Stefan, King, Randall W., Lee, Jiing-Dwan, Herrgard, Sanna, Zarrinkar, Patrick, and Gray, Nathanael S.
- Subjects
- *
PROTEIN kinases , *ENZYME inhibitors , *FURANS , *THIAZOLES , *DIAZEPINES , *CHEMICAL biology - Abstract
Summary: Selective protein kinase inhibitors have only been developed against a small number of kinase targets. Here we demonstrate that “high-throughput kinase profiling” is an efficient method for the discovery of lead compounds for established as well as unexplored kinase targets. We screened a library of 118 compounds constituting two distinct scaffolds (furan-thiazolidinediones and pyrimido-diazepines) against a panel of 353 kinases. A distinct kinase selectivity profile was observed for each scaffold. Selective inhibitors were identified with submicromolar cellular activity against PIM1, ERK5, ACK1, MPS1, PLK1-3, and Aurora A,B kinases. In addition, we identified potent inhibitors for so far unexplored kinases such as DRAK1, HIPK2, and DCAMKL1 that await further evaluation. This inhibitor-centric approach permits comprehensive assessment of a scaffold of interest and represents an efficient and general strategy for identifying new selective kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
14. In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
- Author
-
Patricelli, Matthew P., Nomanbhoy, Tyzoon K., Wu, Jiangyue, Brown, Heidi, Zhou, David, Zhang, Jianming, Jagannathan, Subadhra, Aban, Arwin, Okerberg, Eric, Herring, Chris, Nordin, Brian, Weissig, Helge, Yang, Qingkai, Lee, Jiing-Dwan, Gray, Nathanael S., and Kozarich, John W.
- Subjects
- *
PROTEIN kinases , *CELLULAR signal transduction , *CELLULAR control mechanisms , *RECOMBINANT proteins , *CARRIER proteins , *ACTIVATION (Chemistry) - Abstract
Summary: Protein kinases are intensely studied mediators of cellular signaling, yet important questions remain regarding their regulation and in vivo properties. Here, we use a probe-based chemoprotemics platform to profile several well studied kinase inhibitors against >200 kinases in native cell proteomes and reveal biological targets for some of these inhibitors. Several striking differences were identified between native and recombinant kinase inhibitory profiles, in particular, for the Raf kinases. The native kinase binding profiles presented here closely mirror the cellular activity of these inhibitors, even when the inhibition profiles differ dramatically from recombinant assay results. Additionally, Raf activation events could be detected on live cell treatment with inhibitors. These studies highlight the complexities of protein kinase behavior in the cellular context and demonstrate that profiling with only recombinant/purified enzymes can be misleading. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling.
- Author
-
Hsu, Peggy P., Kang, Seong A., Rameseder, Jonathan, Yi Zhang, Ottina, Kathleen A., Lim, Daniel, Peterson, Timothy R., Yongmun Choi, Gray, Nathanael S., Yaffe, Michael B., Marto, Jarrod A., and Sabatini, David M.
- Subjects
- *
PROTEIN kinases , *RAPAMYCIN , *REGULATION of cell growth , *RESEARCH methodology , *MASS spectrometry , *GROWTH factors , *CELLULAR control mechanisms - Abstract
The mammalian target of rapamycin (mTOR) protein kinase is a master growth promoter that nucleates two complexes, mTORC1 and mTORC2. Despite the diverse processes controlled by mTOR, few substrates are known. We defined the mTOR-regulated phosphoproteome by quantitative mass spectrometry and characterized the primary sequence motif specificity of mTOR using positional scanning peptide libraries. We found that the phosphorylation response to insulin is largely mTOR dependent and that mTOR exhibits a unique preference for proline, hydrophobic, and aromatic residues at the +1 position. The adaptor protein Grb10 was identified as an mTORC1 substrate that mediates the inhibition of phosphoinositide 3-kinase typical of cells lacking tuberous sclerosis complex 2 (TSC2), a tumor suppressor and negative regulator of mTORC1. Our work clarifies how mTORC1 inhibits growth factor signaling and opens new areas of investigation in mTOR biology. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
16. Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein
- Author
-
Yang, Qingkai, Deng, Xianming, Lu, Bingwen, Cameron, Michael, Fearns, Colleen, Patricelli, Matthew P., Yates, John R., Gray, Nathanael S., and Lee, Jiing-Dwan
- Subjects
- *
CARCINOGENESIS , *CANCER cells , *PROTEIN kinases , *CANCER treatment , *PHOSPHORYLATION , *TRANSCRIPTION factors ,TUMOR growth prevention - Abstract
Summary: BMK1 is activated by mitogens and oncogenic signals and, thus, is strongly implicated in tumorigenesis. We found that BMK1 interacted with promyelocytic leukemia protein (PML), and inhibited its tumor-suppressor function through phosphorylation. Furthermore, activated BMK1 notably inhibited PML-dependent activation of p21. To further investigate the BMK-mediated inhibition of the tumor suppressor activity of PML in tumor cells, we developed a small-molecule inhibitor of the kinase activity of BMK1, XMD8-92. Inhibition of BMK1 by XMD8-92 blocked tumor cell proliferation in vitro and significantly inhibited tumor growth in vivo by 95%, demonstrating the efficacy and tolerability of BMK1-targeted cancer treatment in animals. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
17. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl
- Author
-
Deng, Xianming, Lim, Sang Min, Zhang, Jianming, and Gray, Nathanael S.
- Subjects
- *
CHEMICAL inhibitors , *ALKYNES , *PROTEIN kinases , *HYDROCARBONS , *GENETIC mutation - Abstract
Abstract: A series of alkyne-containing type II inhibitors with potent inhibitory activity of T315I Bcr-Abl has been identified. The most active compound 4 exhibits an EC50 of less than 1nM against wild-type Bcr-Abl and an EC50 of 10nM against T315I mutant but is broadly active against a number of other kinases. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
18. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
- Author
-
Fabbro, Doriano, Manley, Paul W., Jahnke, Wolfgang, Liebetanz, Janis, Szyttenholm, Alexandra, Fendrich, Gabriele, Strauss, Andre, Zhang, Jianming, Gray, Nathanael S., Adrian, Francisco, Warmuth, Markus, Pelle, Xavier, Grotzfeld, Robert, Berst, Frederic, Marzinzik, Andreas, Cowan-Jacob, Sandra W., Furet, Pascal, and Mestan, Jürgen
- Subjects
- *
PROTEIN kinases , *ADENOSINE triphosphate , *BINDING sites , *THERAPEUTIC use of proteins , *DRUG resistance , *DRUG approval , *PROTEIN structure - Abstract
Abstract: The ATP-competitive inhibitors dasatinib and nilotinib, which bind to catalytically different conformations of the Abl kinase domain, have recently been approved for the treatment of imatinib-resistant CML. These two new drugs, albeit very efficient against most of the imatinib-resistant mutants of Bcr–Abl, fail to effectively suppress the Bcr–Abl activity of the T315I (or gatekeeper) mutation. Generating new ATP site-binding drugs that target the T315I in Abl has been hampered, amongst others, by target selectivity, which is frequently an issue when developing ATP-competitive inhibitors. Recently, using an unbiased cellular screening approach, GNF-2, a non-ATP-competitive inhibitor, has been identified that demonstrates cellular activity against Bcr–Abl transformed cells. The exquisite selectivity of GNF-2 is due to the finding that it targets the myristate binding site located near the C-terminus of the Abl kinase domain, as demonstrated by genetic approaches, solution NMR and X-ray crystallography. GNF-2, like myristate, is able to induce and/or stabilize the clamped inactive conformation of Abl analogous to the SH2-Y527 interaction of Src. The molecular mechanism for allosteric inhibition by the GNF-2 inhibitor class, and the combined effects with ATP-competitive inhibitors such as nilotinib and imatinib on wild-type Abl and imatinib-resistant mutants, in particular the T315I gatekeeper mutant, are reviewed. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
19. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
- Author
-
Wenjun Zhou, Ercan, Dalia, Liang Chen, Cai-Hong Yun, Li, Danan, Capelletti, Marzia, Cortot, Alexis B., Chirieac, Lucian, Iacob, Roxana E., Padera, Robert, Engen, John R., Kwok-Kin Wong, Eck, Michael J., Gray, Nathanael S., and Jänne, Pasi A.
- Subjects
- *
EPIDERMAL growth factor , *PROTEIN kinases , *CELL receptors , *GENETIC mutation , *LUNG cancer , *DRUG resistance in cancer cells , *QUINAZOLINE , *CANCER cells , *RESEARCH - Abstract
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
20. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1.
- Author
-
Thoreen, Carson C., Kang, Seong A., Jae Won Chang, Qingsong Liu, Jianming Zhang, Yi Gao, Reichling, Laurie J., Sim, Taebo, Sabatini, David M., and Gray, Nathanael S.
- Subjects
- *
ADENOSINE triphosphate , *RAPAMYCIN , *REGULATION of cell growth , *PROTEIN kinases , *ALLOSTERIC proteins , *PHOSPHORYLATION , *GENE targeting , *PHYSIOLOGY - Abstract
The mammalian target of rapamycin (mTOR) kinase is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2, that coordinately promote cell growth, proliferation, and survival. Rapamycin is a potent allosteric mTORC1 inhibitor with clinical applications as an immunosuppressant and anti-cancer agent. Here we find that Torini, a highly potent and selective ATP-competitive mTOR inhibitor that directly inhibits both complexes, impairs cell growth and proliferation to a far greater degree than rapamycin. Surprisingly, these effects are independent of mTORC2 inhibition and are instead because of suppression of rapamycin-resistant functions of mTORC1 that are necessary for cap-dependent translation and suppression of autophagy. These effects are at least partly mediated by mTORC 1-dependent and rapamycin-resistant phosphorylation of 4E-BP1. Our findings challenge the assumption that rapamycin completely inhibits mTORC1 and indicate that direct inhibitors of mTORC1 kinase activity may be more successful than rapamycin at inhibiting tumors that depend on mTORC1. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
21. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
- Author
-
Hur, Wooyoung, Velentza, Anastasia, Kim, Sungjoon, Flatauer, Laura, Jiang, Xinnong, Valente, David, Mason, Daniel E., Suzuki, Melissa, Larson, Brad, Zhang, Jianming, Zagorska, Anna, DiDonato, Michael, Nagle, Advait, Warmuth, Markus, Balk, Steven P., Peters, Eric C., and Gray, Nathanael S.
- Subjects
- *
ENZYME inhibitors , *EPIDERMAL growth factor , *PROTEIN kinases , *ADENOSINE triphosphate , *BINDING sites , *QUINAZOLINE - Abstract
Abstract: Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket. Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members. We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clinical stage EGFR inhibitors such as CI-1033. This cross-reactivity may have significant clinical implications. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
22. A chemical switch for inhibitor-sensitive alleles of any protein kinase.
- Author
-
Bishop, Anthony C., Ubersax, Jeffrey A., Petsch, Dejah T., Matheos, Dina P., Gray, Nathanael S., Blethrow, Justin, Shimizu, Eiji, Tsien, Joe Z., Schultz, Peter G., Rose, Mark D., Wood, John L., Morgan, David O., and Shokat, Kevan M.
- Subjects
- *
PROTEIN kinases , *CHEMICAL inhibitors , *PROTEINS , *YEAST , *GENETICS - Abstract
Describes a chemical genetic strategy for sensitizing protein kinases to cell-permeable molecules that do not inhibit wild-type kinases. Methods, which included the analysis of a budding yeast strain carrying an inhibitor-sensitive form of the cyclin-dependent kinase Cdc28 (CDK1) in place of the wild-type protein; Implications of the strategy.
- Published
- 2000
- Full Text
- View/download PDF
23. The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.
- Author
-
Wells, Carrow I., Al-Ali, Hassan, Andrews, David M., Asquith, Christopher R. M., Axtman, Alison D., Dikic, Ivan, Ebner, Daniel, Ettmayer, Peter, Fischer, Christian, Frederiksen, Mathias, Futrell, Robert E., Gray, Nathanael S., Hatch, Stephanie B., Knapp, Stefan, Lücking, Ulrich, Michaelides, Michael, Mills, Caitlin E., Müller, Susanne, Owen, Dafydd, and Picado, Alfredo
- Subjects
- *
PROTEIN kinase inhibitors , *KINASE inhibitors , *KINASES , *PROTEIN kinases - Abstract
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing.
- Author
-
Li, Zhengnian, Powell, Chelsea E., Groendyke, Brian J., Gero, Thomas W., Feru, Frederic, Feutrill, John, Chen, Bailing, Li, Bin, Szabo, Hilary, Gray, Nathanael S., and Scott, David A.
- Subjects
- *
CANCER treatment , *PROTEIN kinases , *ALANINE , *TARGETED drug delivery , *UREA - Abstract
The protein kinase TNK2 (ACK1) is an emerging drug target for a variety of indications, in particular for cancer where it plays a key role transmitting cell survival, growth and proliferative signals via modification of multiple downstream effectors by unique tyrosine phosphorylation events. Scaffold morphing based on our previous TNK2 inhibitor XMD8-87 identified urea 17 from which we developed the potent and selective compound 32. A co-crystal structure was obtained showing 32 interacting primarily with the main chain atoms of an alanine residue of the hinge region. Additional H-bonds exist between the urea NHs and the Thr205 and Asp270 residues. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
- Author
-
Huang, Hai-Tsang, Dobrovolsky, Dennis, Paulk, Joshiawa, Yang, Guang, Weisberg, Ellen L., Doctor, Zainab M., Buckley, Dennis L., Cho, Joong-Heui, Ko, Eunhwa, Jang, Jaebong, Shi, Kun, Choi, Hwan Geun, Griffin, James D., Li, Ying, Treon, Steven P., Fischer, Eric S., Bradner, James E., Tan, Li, and Gray, Nathanael S.
- Subjects
- *
UBIQUITIN , *LIGASES , *PHARMACOLOGY , *PROTEIN kinases , *PROTEOMICS - Abstract
Summary Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degradation represent an emerging pharmacological strategy. A major unanswered question is how generally applicable this strategy is to all protein targets. In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quantitative proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable. This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degradation requires more than target engagement. The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment. Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clinical developments. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.